935680-90-3

Usage

Uses

Used in Pharmaceutical Industry:
5-tert-butyl-2,3-dihydro-1H-inden-1-aMine is used as an intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into complex molecular structures. Its presence in these structures can contribute to the development of new drugs with improved therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 5-tert-butyl-2,3-dihydro-1H-inden-1-aMine is utilized as a precursor in the production of agrochemicals. Its role in the synthesis of these compounds can lead to the creation of more effective and targeted pesticides or other agricultural products.
Used in Organic Synthesis:
5-tert-butyl-2,3-dihydro-1H-inden-1-aMine is used as a building block in organic synthesis, particularly for the preparation of heterocyclic compounds. Its structural versatility allows for the formation of a wide range of chemical entities with diverse applications.
Used in Medicinal Chemistry:
Due to its structural features, 5-tert-butyl-2,3-dihydro-1H-inden-1-aMine has potential applications in medicinal chemistry. It can be used in the design and synthesis of new drug candidates, contributing to advancements in the treatment of various diseases and conditions.

InChI:InChI=1/C13H19N/c1-13(2,3)10-5-6-11-9(8-10)4-7-12(11)14/h5-6,8,12H,4,7,14H2,1-3H3

Upstream product

• 1374781-07-3 (Z)-5-tert-butyl-2,3-dihydro-1H-inden-1-one oxime 
• 28547-33-3 1-(4-(tert-butyl)phenyl)-3-chloropropan-1-one 
• 4600-86-6 5-(tert-butyl)-2,3-dihydro-1H-inden-1-one 
• 253185-03-4 tert-butylbenzene 
• 1056038-54-0 (Z)-5-tert-butyl-2,3-dihydro-1H-inden-1-one O-methyl oxime 
• 935680-89-0 5-tert-butyl-1-indanone O-methyloxime 

Downstream Products

• 808756-71-0 N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N'-1H-indazol-4-ylurea 
• 934593-36-9 (1R)-5-tert-butyl-indan-1-ylamine tosylate 
• 808756-83-4 (1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-ylamine 

Relevant academic research and scientific papers

SUBSTITUTED BICYCLIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted bicyclic carboxamide and urea derivatives, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions.

Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H- indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management

Vanilloid receptor TRPV1 is a cation channel that can be activated by a wide range of noxious stimuli, including capsaicin, acid, and heat. Blockade of TRPV1 activation by selective antagonists is under investigation by several pharmaceutical companies in an effort to identify novel agents for pain management. Here we report that replacement of substituted benzyl groups by an indan rigid moiety in a previously described N-indazole-N′-benzyl urea series led to a number of TRPV1 antagonists with significantly increased in vitro potency and enhanced drug-like properties. Extensive evaluation of pharmacological, pharmacokinetic, and toxicological properties of synthesized analogs resulted in identification of (R)-7 (ABT-102). Both the analgesic activity and drug-like properties of (R)-7 support its advancement into clinical pain trials.

Development of a large scale asymmetric synthesis of vanilloid receptor (TRPV1) antagonist ABT-102

A highly efficient asymmetric synthesis of TRPV1 antagonist ABT-102 was developed and successfully demonstrated on a multi-kilogram scale. This process incorporates a new asymmetric synthesis of (R)-tert-butylaminoindan, which is based on a chiral auxiliary induced diastereoselective reduction of its iminoindan precursor.

Prodrugs of compounds that inhibit TRPV1 receptor

Compounds of formula (I) wherein A, R1, R2, and R3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladd

Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity.